A team of doctors in Australia have trial tested the drug rapamycin in the treatment of a patient said to have<unk>  and have found it to be an effective remedy. However, the diagnosis of<unk>  in this patient has been questioned by others. The<unk>  research team in the National Human Genome Research Institute at the United States National Institutes of Health have initiated a Phase 0 dose finding trial with the AKT1 inhibitor ARQ 092, which is being developed by the Arqule Corporation. In earlier tests on tissue and cell samples obtained from patients, ARQ 092 reduced phosphorylation of AKT and downstream targets of AKT in as little as two hours. The Phase 0 trial opened in November 2015. This trial is based on in vitro data showing inhibition of AKT1 in cell lines from patients with<unk> .
Proteus syndrome
Gulf War syndrome
Toxic shock syndrome
Majeed syndrome
Proteus-like syndrome
Enterotoxemia
Crush syndrome
Multiple organ dysfunction syndrome